SCHEMBL3105322

SCHEMBL3105322

CCNC(=O)c1ccc(-n2nnc(C(=O)NC3CC3)c2COc2cc(F)c(F)c(F)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 1/20 0.42
MAPK14 Q16539 10/20 0.39
CYP2C9 P11712 7/20 0.39
MAPK11 Q15759 3/20 0.37
RXFP1 Q9HBX9 1/20 0.37
SLC6A5 Q9Y345 1/20 0.36
BUB1 O43683 1/20 0.36
PRKACG P22612 1/20 0.36
MAPKAPK2 P49137 1/20 0.36
ACSL5 Q9ULC5 1/20 0.36
STK24 Q9Y6E0 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C19 P33261 2/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
RECQL P46063 1/20 0.36
F2 P00734 1/20 0.36
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3117490 0.92 GABRA5 (0.42) GABRA5MAPK14CYP2C9RXFP1SLC6A5
SCHEMBL3108727 0.92 GABRA5 (0.44) GABRA5MAPK14CYP2C9RXFP1SLC6A5
SCHEMBL3109658 0.90 ATF4 (0.41) GABRA5MAPK14CYP2C9SLC6A5PDE4B
SCHEMBL3100891 0.89 GABRA5 (0.47) GABRA5MAPK14RXFP1SLC6A5ALDH1A1
SCHEMBL3099810 0.89 GABRA5 (0.41) GABRA5MAPK14CYP2C9RXFP1CYP1A2
SCHEMBL3099701 0.89 GABRA5 (0.39) GABRA5MAPK14CYP2C9RXFP1SLC6A5
SCHEMBL3107846 0.88 ALDH1A1 (0.40) GABRA5MAPK14CYP2C9RXFP1SLC6A5
SCHEMBL3099680 0.88 GABRA5 (0.43) GABRA5CYP2C9RXFP1CYP1A2CYP2C19
SCHEMBL3117606 0.88 SLC6A5 (0.45) GABRA5SLC6A5CYP1A2CYP2C19CYP2D6
SCHEMBL3104755 0.88 GABRA5 (0.42) GABRA5MAPK14CYP2C9MAPK11BUB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 GABRA5 755/4885MAPK14 1769/4885CYP2C9 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.